Johns Hopkins Medicine Nov 18 2025 A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of treatment.  Results from the phase 2 clinical trial (NCT03521830), presented Oct. 20 at the European Society for Medical Oncology (ESMO) annual meeting, show that first-line nivolumab, a PD-1 immune checkpoint inhibitor, produced an objective response rate (ORR)